MediRama

Contact us LinkedIn

Resources

Share recent publications on regulatory trends, FDA programs, and oncology clinical trial
strategies, such as articles by MediRama's team on oncology drug development.

Total 132

View More

Rapidly Evolving Trends in Oncology Drug Development: "Failing to Keep Up Means Failing in Clinical Development"

  • 2026.07.18
  • Souce: Medical Times
View More

"ASCO 2026 Signals a Shift in the Standard of Care": MediRama CEO Dr. Hanlim Moon Highlights Five Landmark Studies

  • 2026.07.16
  • Souce: THE BIO
View More

MediRama Brings Together the Latest Trends in Global Oncology Drug Development at the "ASCO 2026 Highlights" Event

  • 2026.07.16
  • Souce: THE BIO
View More

GI Innovation and MediRama Receive Approval for Clinical Trial Amendment of Co-developed GI-108, Targeting Completion by 2029

  • 2026.07.10
  • Souce: Data Investment
View More

[Moon Han-lim's ASCO 2026 Report ⑤] The Promise of Korean Biotechnology

  • 2026.07.10
  • Souce: THE BIO
View More

[Moon Han-lim's ASCO 2026 Report ④] ADCs and China's Rise: Is the Center of Innovation Shifting?

  • 2026.07.01
  • Souce: THE BIO
View More

[Moon Han-lim's ASCO 2026 Report ③] Daraxonrasib: A New Therapeutic Opportunity for Pancreatic Cancer Extending to KRAS Wild-Type Disease

  • 2026.07.01
  • Souce: THE BIO
View More

[Moon Han-lim’s ASCO 2026 Report ②] The Question Raised by PROTEUS: Can pCR Serve as a Valid Surrogate Endpoint in Prostate Cancer?

  • 2026.06.12
  • Souce: THE BIO
View More

[Moon Han-lim's ASCO 2026 Coverage ①] The EA5142 Setback: Does Every Patient Need Postoperative Immunotherapy?

  • 2026.06.09
  • Souce: THE BIO
View More

[EDGE Column] A New Strategy to Overcome Anticancer Drug Resistance: The Emergence of Lifyorli™ - A Paradigm Shift in the Treatment of Platinum-Resistant Ovarian Cancer

  • 2026.06.05
  • Souce: THE BIO